(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 April 2010 (29.04.2010)

PCT

(10) International Publication Number
WO 2010/048026 A3

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/US2009/060840

(22) **International Filing Date**:
15 October 2009 (15.10.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/196,855 20 October 2008 (20.10.2008) US

(71) **Applicant** *(for all designated States except US)*: **IMCLONE LLC** [US/US]; 180 Varick Street, New York, New York 10014 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **SUN, Haijun** [US/US]; Imclone Llc, 180 Varick Street, New York, New York 10014 (US). **LIU, Ling** [US/US]; 3393 Kilkenny Circle, Carmel, Indiana 46032 (US).

(74) **Agents**: **HASON, Averie, K.** et al.; Eli Lilly And Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
15 July 2010

WO 2010/048026 A3

(54) **Title**: FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR-3) INHIBITORS AND METHODS OF TREATMENT

(57) **Abstract**: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3 (IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer. X18531